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Abstract
Graves’ disease (GD) is an autoimmune disorder characterized by presence of 
TSH receptor autoantibody. It is most common cause of hyperthyroidism world-
wide. Though GD can occur any age but peak incidence is seen during adulthood in 
between 20 to 50 years of age. GD is more commonly seen in female. GD is primar-
ily disease of thyroid gland but affects multi organ system i.e. heart, liver, muscle, 
eye and skin. Symptoms and signs are result from hyperthyroidism or a conse-
quence of underlying autoimmunity. Weight loss, fatigue, heat intolerance, tremor, 
and palpitations are the most common symptoms. Diffuse goiter presents in most 
of younger patients with thyrotoxicosis but less common in older patients. Graves’ 
ophthalmopathy and pretibial myxedema are extrathyroidal manifestations of GD 
which results from action of TSHR autoantibodies on TSHR present onfibroblast, 
adipocyte and T cells in extrathyroidal tissue. Treatment of GD remains in between 
antithyroid drugs, radioiodine or surgery. In this review we discuss the diagnosis 
and management of GD.
Keywords: autoimmune thyroid disease, Graves’ disease, hyperthyroidism, 
radioactive iodine
1. Introduction
Graves’ disease (GD) is the most common cause of hyperthyroidism worldwide 
[1, 2]. It was first described by German physician Carl Adolf Von Basdow. It is an 
autoimmune disorder characterized by presence of TSH receptor autoantibody [3]. 
These autoantibodies stimulate TSH receptors on thyroid cells and cause hyper-
trophy and hyperplasia resulting thyroid gland enlargement. TSHR autoantibodies 
also cause increased synthesis and secretion of thyroid hormones. GD is primarily 
disease of thyroid gland but affects multi organ system i.e. heart, liver, muscle, 
eye and skin. Graves’ ophthalmopathy and pretibial myxedema are extrathyroidal 
manifestations of GD which results from action of TSHR autoantibodies on TSHR 
present onfibroblast, adipocyte and T cells in extrathyroidal tissue.
2. Epidemiology
Graves’ disease accounts for 70–80% cases of hyperthyroidism in iodine suf-
ficient population, where as it accounts for 50% cases of hyperthyroidism in iodine 
deficient areas of world [4, 5].
Annual incidence for GD is 20–50 person per 100,000 population and life time 
risk for developing GD is 3% for women and 0.5% for men [6, 7]. Though GD can 
occur any age but peak incidence is seen during adulthood in between 20 to 50 years 
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of age [8]. GD is more common in Caucasians as compare to Asian and least common 
among black African [9, 10]. The annual incidence of thyroid associated orbitopathy is 
16 cases per 100000 in women and 3 cases per 100000 in men and is more in smokers 
[11]. Pretibial myxedema is a very rare complication of GD, is seen in 1.5 cases per 
100000 case of GO [12]. Studies have shown that GD with nodule formation have 
higher incidence of thyroid carcinoma perticularly tall Cell Variant of papillary thyroid 
cancer (a more aggressive form of cancer) was significantly more common [13, 14].
3. Risk factors
3.1 Genetic factors
Genetic component is considered a major risk factor for development of GD. 
Twin studies show concordance rate of GD in monozygotic twins in between 0.29 to 
0.36, and in dizygotic twins between 0.00 and 0.04 [15]. GD predisposition appears 
to be polygenic [16]. Recently, bioinformatics and next-generation sequencing 
(NGS) based pangenomic analyses have identified many predisposing genes which 
are implicated in autoimmune disease, autoimmune thyroid disease and Graves’ 
disease [16]. These are various genes which take part into the pathogenesis of GD: 
cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), TSH-R, Tg, CD40, protein 
tyrosine phosphatase-22 (PTPN 22), HLA, and CD25 [17]. Association with various 
HLA region is also seen, DR3 haplotype (i.e. DQB1*02, DQA1*0501, DRB1*03) pre-
disposes to GD, whereas the DR7 haplotype (i.e., DQA1*0201, DQB1*0302, DRB1*07 
or DQA1*0201, DQB1*02, DRB1*07) appears to be protective [18].
3.2 Sex
GD is more commonly seen in female, and estrogen receptor ESR2 polymorphisms 
are frequently seen in GD. Association of disease fluctuation and estrogen level varia-
tions which are seen during pregnancy, the menstrual cycle, and menopause further 
clarify its role in pathophysiology of the disease [19]. Estrogen receptor expression is 
present on orbital fibroblasts, and glucocorticoids can modulate it [20].
3.3 Environmental factors
Smoking adversely affects immune system and thyroid gland health. Current 
smoking doubles the risk of Graves’ hyperthyroidism and triples the risk of devel-
oping Graves’ ophthalmopathy (GO) the effect was found to be dose dependent and 
more pronounced in women [21–23]. Conversely four large studies confirm that 
smoking decreases the risk of hypothyroidism and autoimmune thyroid diseases 
(AITD) by decreasing Anti-TPO antibodies [24–27]. Three large studies have shown 
that smoking lowers the serum TSH level accompanied by slight increase in serum 
level of FT3 and FT4 and this effect is dose dependent [23, 28, 29].
Pestisides and halogenated organochlorides have thyroid disrupting properties that 
can alter the thyroid functions by binding to thyroid hormone transport proteins [30].
3.4 Stress
Relationship in between stressful life events and onset of GD was documented 
in 1825. Major stress is positively associated with increased risk of GD. By modulat-
ing the cortisol pathway stress can alter the course of many other autoimmune 
diseases also [31].
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3.5 Pregnancy
Pregnancy is associated with major changes in thyroid anatomy and physiology. 
Hyperthyroidism of GD is increased in early pregnancy and during postpartum. 
As pregnancy advances GD tends to improve which may be due to better maternal 
immune tolerance or altered B cell and T cell functions [32]. Decrease immune 
tolerance after delivery may cause increase in autoimmune thyroid diseases in 
postpartum [33].
3.6 Viruses
Many viruses affect the thyroid gland some of which associated with presence of 
thyroid autoantibodies i.e. congenital rubella, hepatitis C virus, subacute thyroid-
itis. But these are not appearing to be associated with development or progression 
of GD [34]. However, the potential influence of various common infections (such 
as Epstein–Barr virus and influenza virus) on the epigenetic characteristics of a 
variety of susceptibility genes remains a major hypothesis for the etiology of GD.
3.7 Iodine and related drugs
Iodine and iodine-containing drugs, such as amiodaroneand iodine-containing 
contrast media, precipitate GD or its recurrence in a genetically susceptible indi-
vidual which may be due to presence of some cryptic epitope on Thyroglobulin 
antibodies [35, 36]. Amiodarone is an iodinated derivative of benzofuran used 
in tachyarrhythmias. Each molecule of amiodarone contains two iodine atoms, 
which constitute 37.5% of its mass and its metabolism results in the daily release of 
approximately 6 mg of free iodine into the circulation which is 20–40 times higher 
than the daily iodine intake. Amiodarone can cause hypothyroidism or thyrotoxi-
cosis by various mechanisms depending on duration of therapy, autoimmunity and 
other characteristics [36].
3.8 Drugs
Various drugs can cause supression of TSH by their direct cytotoxic effect on 
thyroid follicular cells. Interferon and ribaverin used in the treatment of HCV 
disease can aggravate hyperthyroidism associated with GD. Highly active antiret-
roviral therapy (HAART) for human immunodeficiency virus (HIV) infection 
Alemtuzumab humanized anti-CD52 monoclonal antibody, Ipilimumab is a 
monoclonal antibody against CTLA4, Nivolumab and pembrolizumab antibodies 
against programmed death protein 1 (PD1) can also precipitate hyperthyroidism by 
immune mechanisms [37–41].
4. Clinical features
Clinical manifestations of Graves’ disease related to age of onset, severity and the 
duration of hyperthyroidism. Symptoms and signs (Table 1) are result from hyper-
thyroidism or a consequence of underlying autoimmunity. Weight loss, fatigue, heat 
intolerance, tremor, and palpitations are the most common symptoms, occurring in 
more than 50% of patients. Elderly person more commonly presents with Weight 
loss, decreased appetite, and cardiac manifestations. Atrial fibrillation is seen in 
more than 10% of elderly but rare in younger patients. Goiter presents in most of 








Tiredness, fatigue, muscle weakness
Heat intolerance, increased sweating
Increased stool frequency




Menstrual disturbances in women (oligomenorrhea or amenorrhea)
Loss of libido
Neck fullness
Eye symptoms (swelling, pain, redness, double vision)
Physical signs of hyperthyroidism
Tachycardia, atrial fibrillation
Systolic hypertension, increased pulse pressure
Cardiac failure
Weight loss
Fine tremor, hyperkinesis, hyperreflexia
Warm, moist skin
Palmar erythema and onycholysis
Muscle weakness
Hair loss
Diffuse, palpable goiter and thyroid bruit
Mental-status and mood changes (e.g., mania or depression)
Extrathyroidal physical signs
Ophthalmopathy
 Eyelid lag, retraction, or both
 Proptosis (exophthalmos)
 Double vision (extraocular-muscle dysfunction)





Developed from: Ref. [7].
Table 1. 
Major symptoms and physical signs in Graves’ disease.
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present most commonly as diffuse thyroid enlargement but nodular goiter can also 
be present perticularly in those who reside in iodine deficient areas (Figure 1).
Varying degree of orbital involvement can be seen in GD which is a consequence 
of thyroid autoimmunity which occur parallel to the thyroid involvement. It usually 
present with tearing, congestion, redness and irritation in eyes. In severe cases 
proptosis may occur due to inflammation and edema of extraoccular muscle and 
retrobulbar tissue expension owing to fluid accumulation as a result of accumula-
tion of glycolsaminoglycan. Double vision and sight threatening complications 
i.e. corneal ulceration, dysthyroid optic neuropathy can occur as a consequence of 
damage to extraoccular muscles. For selecting appropriate patient for treatment 
EUGOGO classified GO in mild, moderate to severe and sight threatening. Activity 
of GO can be easily assessed by clinical activity score (CAS) (Table 2). A CAS ≥3/7 




Pain on attempted up- or down gaze
Redness of the eyelids
Redness of the conjunctiva
Swelling of the eyelids
Inflammation of the caruncle and = or plica
Conjunctival oedema
A CAS ≥3/7 indicates active GO.
Developed from: Ref. [42].
Table 2. 
Measures of clinical activity score (CAS).
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Graves’ dermopathy is seen in 1–4% case of GD. It frequently localize to pretibial 
region but it may be seen on elbow, feet, toe and areas of trauma. Lesion can be 
described as erythematous, non-pitting thickening of dermis in pretibial region. In 
mild cases it gives “orange Peel” appearance. Graves’ dermopathy is almost always 
associated with GO (Figure 3).
Acropachy is very rare extrathyroidal manifestation of GD. Acropachy is defined as 
skin tightness, digital clubbing, small-joint pain, and soft tissue edema progressing over 
months or years with gradual curving and enlargement of the fingers [43]. The patho-
genesis of acropachy is not known. In most of cases acropachy remain asymptomatic.
5. Diagnosis
5.1 Graves’ hyperthyroidism
Diagnosis of GD is based on clinical manifestations of thyrotoxicosis and bio-
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in the absence of orbitopathy serum TSH Receptor Antibody (TRAb) and imaging 
may be required to for the diagnosis.
5.2 Biochemical evaluation
5.2.1 Thyroid hormones
Serum TSH measurement has the highest sensitivity and specificity of any single 
blood test used in the evaluation of suspected thyrotoxicosis [44]. Diagnostic accu-
racy improves when a serum TSH, free T4, and total T3 are assessed at the initial 
evaluation. In overt hyperthyroidism, serum free T4, T3, or both are elevated, and 
serum TSH is subnormal (usually <0.01 mU/L in a third-generation assay). In mild 
hyperthyroidism, serum T4 and free T4 can be normal, only serum T3 may be ele-
vated, and serum TSH will be low or undetectable. These laboratory findings have 
been called “T3-toxicosis” and may represent the earliest stages of hyperthyroidism 
caused by GD [45]. Ratio of total T3 to T4 may also be useful in differentiating GD 
from thyroiditis. In one study the ratio of total T3 to total T4 (ng/lg) was >20 in GD 
and toxic nodular goiter, and <20 in painless or postpartum thyroiditis [46].
5.2.2 TSH receptor antibodies (TRAb)
In a hyperthyroid patient with a diffuse goiter and recent history of orbitopathy, 
the diagnosis of GD is likely so no further testing is required but hyperthyroid 
patient with a diffuse goiter and no definite orbitopathy, TRAb measurement can be 
of useful in distinguish GD from other etiologies.
5.3 Imaging
5.3.1 Thyroid ultrasound
Currently ultrasonography has become an important and practical tool for 
the thyroidologist; beside its role in thyroid nodule it can easily distinguish toxic 
multinodular goiter from GD. Increased blood flow in Doppler ultrasonography can 
distinguish GD from thyroiditis where blood flow is decreased.
5.3.2 Radioiodine uptake (RAIU) and thyroid scan
RAIU measures the percentage of administered RAI that is concentrated into 
thyroid tissue after a fixed interval, usually 24 hours. Technetium uptake measure-
ments utilize pertechnetate that is trapped by the thyroid, but not organified. A 
technetium (TcO4) uptake measures the percentage of administered technetium 
that is trapped by the thyroid after a fixed interval, usually 20 minutes. Uptake 
study is not indicated routinely. It is recommended only when diagnosis is difficult. 
Uptake is increased in GD, toxic multinodular goiter and toxic adenoma. Uptake is 
decreased in subacute, postpartum, painless thyroiditis.
6. Management
After establishing the diagnosis of GD treatment options include antithyroid 
drugs, radioiodine, and surgery. Although RAI is preferred in United States and 
ATDs in Europe but long term quality of life was found to be same in all three 
treatment group [47]. Selection of treatment depends on local availability, cost of 
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treatment, presence of active GO and physician preference. The main goal of man-
agement is to normalize thyroid hormones level and make the patient asymptomatic.
6.1 Pharmacological therapy
6.1.1 Antithyroid drugs
Thionamides are class of ATDs which inhibit thyroid peroxidase thereby inhibit 
thyroid hormone synthesis. Methimazole (MMI) and propylthiourecil (PTU) are 
used in United States where as Carbimazole (converted to methimazole in liver) is 
used in other part of world. MMI is preferred over PTU as initial therapy because 
of long duration of action and reduced risk of major side effect, except during first 
trimester of pregnancy where PTU is preferred because of lesser teratogenic effects 
[48]. Starting dose of MMI is 10 to 30 mg daily and of PTU is 50 to 10 mg three 
times daily. Dose of ATDs should be kept lowest to maintain T4 in normal range 
because higher doses are associated with high risk of adverse effect. Adverse effect 
of ATDs can be divided in minor allergic reaction and serious allergic/toxic effects 
agranulocytosis, liver injury and vacuities [48–52]. Hepatotoxicity and agranulo-
cytosis are seen more commonly with propylthiouracil. Initial complete blood cell 
count and liver function test required before starting these drugs and patient should 
be instructed to report if he develops high grade fever with sore throat. American 
Thyroid Association recommends ATDs should be continued for 12–18 months if 
chosen as primary therapy then can be discontinued if TSH and TRAb levels are 
normal. Remission rate with ADTs treatment is 40–60% and is not associated with 
duration and dose of ATDs. If patient becomes hyperthyroid after completion of 
treatment, RAI or thyroid surgery should be considered.
6.1.2 Beta-adrenergic blocker
Beta-adrenergic blocker should be given to all symptomatic thyrotoxic patients, 
especially elderly. Goal of beta blocker treatment is to decrease heart rate less than 
90 per minute. Propranolol is preferred non-selective beta blocker which decreases 
deiodinationof T4 to T3 [53]. In patient with asthma, obstructive airway disease  
and Raynaud’s phenomenon selective β1 blocker can be used with cautions.  
Calcium channel blockers verapamil and diltiazem can be used when β blockers are  
contraindicated [45].
6.1.3 Lithium
Lithium carbonate inhibits secretion of thyroid hormones. It does not decrease 
the efficacy of RAI so it can be used to control hyperthyroidism during RAI therapy 
or in patient who are allergic to ATDs.
6.1.4 Cholestyramine
It interfarewith enterohepatic circulation thereby decrease thyroid hormone 
leves rapidly. It can be used as adjunctive therapy in resistant thyrotoxicosis.
6.2 Radioactive iodine
RAI is one of definitive treatment for GD. It has been used for more than seven 
decade in the management of GD. Effect of ionizing radiation leads to cellular death 
and consequently reduction in functioning thyroid tissue and thyroid size. The goal 
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of RAI is to render the patient hypothyroid for that 10–15 mci dose is sufficient in 
most of the patients. RAI can be used as primary therapy in mild cases but in severe 
thyrotoxic patient β blockers and ATDs are used first to render the patient euthyroid 
to avoid radiation induced thyroiditis. ATDs should be discontinued 2–3 days prior 
and till 3–7 day of RAI treatment to enhance the efficacy of treatment. Regular 
follow up should be at 4–6 weeks interval with biochemical testing include TSH, 
FT4 and T3 till 6 months or till patient become hypothyroid. Around 40% of 
patient treated with RAI become hypothyroid by 8 weeks and 80% by 16 weeks 
[54]. Levothyroxine replacement therapy should be started once patient become 
hypothyroid. Most of studies found no increase in prevalence of thyroid cancer or 
secondary malignancy in RAI treated patients. RAI is associated with development 
and worsening of orbitopathy as compare to ATDs and thyroid surgery [55, 56]. So 
presence of orbitopathy may influence the treatment option.
6.3 Thyroid surgery
Thyroid surgery is least preferred treatment option for GD. It’s preferred when 
large nodular goiter is present. Total or Near-total thyroidectomy is procedure 
of choice if surgery is chosen as treatment option. Patient should be rendered 
euthyroid before surgery by ATDs and β blockers to minimize risk of thyroid 
storm [57]. Saturated solution of potassium iodide (SSKI) may be used preopera-
tively to normalize thyroid functions and to decrease the vascularity of thyroid 
gland [58]. ATA recommends measurement of calcium and 25-hydroxy vitamin 
D before surgery and if abnormal then should be normalized. Surgery should be 
performed by experienced surgeon at high volumeCentre to minimize postoperative 
 complications [59].
6.4 Treatment of Graves’ orbitopathy in patients with Graves’ disease
The optimal treatment of GO require restoration of euthyroidism and manage-
ment of orbitopathy. Smoking should be discouraged as smoking increases progres-
sion and severity of GO and worsens the outcome [60]. Management of orbitopathy 
depends on its severity and activity. Mild inactive disease can be managed con-
servatively by artificial tear films only. In severe and active disease intravenous 
pulse steroid therapy may be required to decrease inflammation. External beam 
radiotherapy has also been used in severe cases. In patient with sight threatening 
and dysthyroid optic neuropathy (DON) orbital decompressive surgery is the only 
option proven to be effective. Rituximab, a anti CD20+ monoclonal antibody that 
causes B Cell depletion shown to be very effective in decreasing severity and activ-
ity od orbitopathy [61].
6.5 Treatment of Graves’ disease during pregnancy
Pregnancy is a hyper vascular state so, clinical signs of thyrotoxicosis and 
normal pregnancy remarkably overlap. Moreover, estrogen induces high serum 
levels of thyroid hormones make the diagnosis difficult. Graves’ disease affects 
0.1–0.2% of pregnancy and carries a considerable risk to mother and new born if 
not controlled adequately [62]. All ATDs are teratogenic and having risk of birth 
defects in new born [63]. During pregnancy ATDs should be used in lowest dose 
to main thyroid hormone levels in upper normal range and monitoring of thyroid 
function should be done monthly. As pregnancy is a state of immune tolerance so 
in about 50% of patients ATDs can be discontinued after first trimester [62]. Breast 
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of TRAb at diagnosis, then at 18–20 weeks of pregnancy, if elevated then repeat at 
30–34 weeks to guide decision regarding fetal monitoring.
6.6 Treatment of dermopathy and acropachy
Treatment of dermopathy and acropachy remain ineffective. Topical and intra-
lesional injection of steroid have been used without substantial success [64]. Trials 
using systemic steroid, rituximab and immunosuppressive drugs are underway with 
mixed results.
7. Emerging therapy
For last many years treatment of Graves’ disease has not been substantially 
changed. In future we can see some great change in management of GD as many 
newer drugs are under trials. These newer therapies are mainly directed to TSH-
receptor. A human anti-TSHR monoclonal antibody (K1–70) is in a phase I trial of 
development [65]. A novel highly selective inhibitor for the TSHR is has promising 
potential for further development for the treatment of GO [66].
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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